Firebrick Pharma, which recently launched its Nasodine povidone-iodine nasal spray in the US as a “nasal hygiene” product, has now announced the launch of Nasodine in Singapore as a germicidal product for protection against infection. As in the US, the nasal spray will now be available to consumers in Singapore via a web site, though Firebrick says that it may be able to sell the nasal spray through pharmacies at some point in the future.
According to Firebrick, Nasodine is considered a topical antiseptic in Singapore and therefore does not require regulatory approval; however prior approval for advertisements for the product is required. The company says that the Singaporean Heath Sciences Authority has now approved its promotions, which will include the tagline “The nasal spray that kills germs.”
In January 2024, Firebrick announced that it had given up on its appeal of a refusal by Australia’s TGA to approve Nasodine for treatment of the common cold, citing the cost and “distraction” of pursuing regulatory approval in Australia after the company had already decided to market the nasal spray as a nasal disinfectant in other countries.
Firebrick Executive Chairman Peter Molloy commented, “We believe that Nasodine will be a valuable product in the wake of the COVID pandemic because of increased awareness and concern about nasal germs.”
Read the Firebrick Pharma press release.
